Inhibition and induction of CYP enzymes in humans: an update

J Hakkola, J Hukkanen, M Turpeinen, O Pelkonen - Archives of Toxicology, 2020 - Springer
The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing
the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies …

Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update

RS Wedemeyer, H Blume - Drug safety, 2014 - Springer
Proton pump inhibitors (PPIs) are used extensively for the treatment of gastric acid-related
disorders, often over the long term, which raises the potential for clinically significant drug …

Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta …

F Milosavljević, N Bukvić, Z Pavlović, Č Miljević… - JAMA …, 2021 - jamanetwork.com
Importance Precise estimation of the drug metabolism capacity for individual patients is
crucial for adequate dose personalization. Objective To quantify the difference in the …

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

T Bauer, HJ Bouman, JW van Werkum, NF Ford… - Bmj, 2011 - bmj.com
Objective To evaluate the accumulated information from genetic association studies
investigating the impact of variants of the cytochrome P450 (CYP) 2C19 genotype on the …

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

S Shi, U Klotz - European journal of clinical pharmacology, 2008 - Springer
Abstract Background Proton pump inhibitors (PPIs) represent drugs of first choice for treating
peptic ulcer, Helicobacter pylori infection, gastrooesophageal reflux disease, nonsteroidal …

Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6

MA Bahar, D Setiawan, E Hak, B Wilffert - Pharmacogenomics, 2017 - Taylor & Francis
Currently, most guidelines on drug–drug interaction (DDI) neither consider the potential
effect of genetic polymorphism in the strength of the interaction nor do they account for the …

Pharmacokinetic drug interaction profiles of proton pump inhibitors

H Blume, F Donath, A Warnke, BS Schug - Drug safety, 2006 - Springer
Proton pump inhibitors are used extensively for the treatment of gastric acid-related
disorders because they produce a greater degree and longer duration of gastric acid …

Drug-drug interaction profiles of proton pump inhibitors

R Ogawa, H Echizen - Clinical pharmacokinetics, 2010 - Springer
Proton pump inhibitors (PPIs) are widely prescribed for the treatment of gastric acid-related
disorders and the eradication of Helicobacter pylori. In addition, they are routinely …

[HTML][HTML] Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients–A review

M Miedziaszczyk, I Idasiak-Piechocka - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Tacrolimus is a calcineurin inhibitor used to prevent rejection in allogenic solid organ
transplant recipients, which is metabolized in the liver with cytochrome P450 isoforms 3A4 …

Effects of the dietary inclusion of a probiotic or prebiotic on florfenicol pharmacokinetic profile in broiler chicken

SA Elgeddawy, HM Shaheen… - Journal of animal …, 2020 - Wiley Online Library
We evaluated the effect of prebiotic or probiotic as feed additives on florfenicol kinetic in
broilers feed. Unsexed two hundred, thirty‐five‐day‐old broiler chickens, were put in four …